Eli Lilly Reveal Positive Clinical Trial Results for Dulaglutide
Eli Lilly has announced the results of their head-to-head clinical study which demonstrates that their investigational GLP-1 glucagon-like peptide 1 receptor agonist, dulaglutide, is just as effective as Novo Nordisk’s Victoza, the market-leader in the area.
The pharmaceutical company revealed the positive top-line results of the sixth clinical trial in their AWARD programme, whereby once-weekly dulaglutide 1.5 mg achieved the primary endpoint of non- inferiority to once-daily Victoza 1.8 mg, as measured by the reduction of haemoglobin A1c (HbA1c) from baseline at 26 weeks. Adverse events were similar across both treatment groups.
The president of Eli Lilly Diabetes, Enrique Conterno, commented that dulaglutide is the only GLP-1 agonist to show non-inferiority against Victoza’s highest-approved dose in a Phase III clinical trial.
The diabetes drug has been submitted to the US and European regulatory bodies (the Food and Drug Administration and the European Medicines Agency). Eli Lilly also noted that all their previous five AWARD clinical trials also achieved the primary endpoint in reduction of HbA1c against placebo and active comparators.